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Purpose 1 
Several risk stratification scores for predicting stroke-associated pneumonia (SAP) have been 2 
derived. We aimed to evaluate the performance and clinical usefulness of such scores for 3 
predicting SAP.  4 
Method 5 
A systematic literature review was undertaken in accordance with the Preferred Reporting 6 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, with application of 7 
the Quality Assessment of Diagnostic Accuracy (QUADAS)-2 tool. Published studies of 8 
hospitalised adults with ischaemic stroke, intracerebral haemorrhage, or both, which derived 9 
and validated an integer-based clinical risk score, or externally validated an existing score to 10 
predict occurrence of SAP, were considered and independently screened for inclusion by two 11 
reviewers.  12 
Findings 13 
We identified 9 scores, from 8 derivation cohorts. Age was a component of all scores, and the 14 
NIHSS score in all except one. 6 scores were internally validated and 5 scores were 15 
externally validated. The A2DS2 score (Age, Atrial fibrillation, Dysphagia, Severity 16 
[NIHSS], Sex) was the most externally validated in 8 independent cohorts. Performance 17 
measures were reported for 8 scores. Discrimination tended to be more variable in the 18 
external validation cohorts (C statistic 0.67-0.83) than the derivation cohorts (C statistic 0.74-19 
0.85).  20 
Discussion 21 
Overall, discrimination and calibration were similar between the different scores. No study 22 
evaluated influence on clinical decision-making or prognosis. 23 
 24 
 25 
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Conclusion 1 
The clinical prediction scores varied in their simplicity of use and were comparable in 2 
performance. Utility of such scores for preventive intervention trials and in clinical practice 3 
remains uncertain and requires further study.  4 
 5 
 6 
  7 
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Introduction 1 
Stroke-associated pneumonia (SAP) is a common and serious complication after acute stroke, 2 
associated with increased length of hospital stay, mortality and worse outcomes in 3 
survivors.1-6 A recent systematic review reported that SAP occurs in 14.3%, although the 4 
frequency varies widely depending on definition of SAP and patient characteristics.7 Several 5 
features of SAP such as varied clinical manifestation,8  uncertain role of  blood biomarkers9 6 
and absence of definitive diagnostic criteria make it challenging to diagnose in clinical 7 
practice. As a first step, the recently convened Pneumonia In Stroke ConsEnsuS (PISCES) 8 
group proposed operational diagnostic criteria for SAP based on Center of Disease Control 9 
criteria (CDC).9  10 
 11 
Numerous baseline clinical factors such as age, dysphagia, severity of stroke, low conscious 12 
level, type and location of stroke may pre-dispose individuals to SAP.10-13  Predictive risk 13 
models derived using these routinely available variables may help in identifying patients at an 14 
increased risk of pneumonia for targeted preventive measures and may also provide 15 
opportunities for novel interventions for monitoring or therapy. However, clinical prediction 16 
scores have several potential weaknesses such as differences in derivation, inconsistent 17 
external validation and complexity thus making choice of score and application to clinical 18 
practice challenging.14,15  We therefore undertook a systematic review to identify scores used 19 
in predicting risk of SAP, with the aim of evaluating performance, usability and utility for 20 
clinical practice and research.  21 
  22 
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Methods 1 
A systematic literature review was undertaken in accordance with the Preferred Reporting 2 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.16  3 
 4 
Data sources and searches 5 
Searches were undertaken in MEDLINE (1946-15th September 2015) and EMBASE (1947-6 
15th September 2015) using pre-defined search criteria and terms (Online only Table I). 7 
Hand searching of reference lists for additional eligible articles was also carried out, and the 8 
PISCES group were invited to provide any other potentially eligible articles.  9 
 10 
Study selection 11 
Published studies (English and Non-English) of hospitalised adults with ischaemic stroke, 12 
intracerebral haemorrhage (ICH), or both, which derived and validated an integer-based 13 
clinical risk score, or externally validated an existing score to predict occurrence of 14 
pneumonia after stroke, were independently screened for eligibility by two reviewers (AKK 15 
and CJS), using the study title and abstract (Online Only Table II). Lead or corresponding 16 
authors of studies under consideration were contacted by e-mail to resolve any issues relating 17 
to assessment of eligibility or data extraction. Discrepancies relating to eligibility or data 18 
extraction were resolved by discussion between the same two study investigators. 19 
 20 
Data Extraction 21 
Data were independently extracted by two reviewers (AKK and CJS) and included study 22 
design, clinical environment, country, stroke subtype (ischaemic or ICH), mean age, mean 23 
National Institutes of Health Stroke Scale (NIHSS) score, components of score and 24 
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weighting, measures of discrimination and calibration, co-morbidities, criteria used in 1 
diagnosis of pneumonia and proportion of patients diagnosed with pneumonia.  2 
 3 
Assessment of quality: risk of bias and applicability 4 
Quality was assessed in terms of risk of bias and concerns regarding applicability, using the 5 
Quality Assessment of Diagnostic Accuracy (QUADAS)-2 tool.17 In brief, judgement of 6 
applicability and risk of bias are made across 4 domains using relevant signalling questions; 7 
patient selection, index risk score, reference standard (diagnosis of SAP) and flow and 8 
timing. The QUADAS-2 tool was applied for each score within the identified validation 9 
cohorts by two reviewers (AKK and AV) independently. 10 
 11 
Risk score performance 12 
For the discriminative ability of scores, we extracted information on the area under the 13 
receiver operating characteristic curve (AUROC) or C-statistic, their 95% confidence 14 
intervals, and the p-value for comparison between models if they were available for both the 15 
derivation and validation cohorts. C-statistic values range from 0.5 (no discrimination, no 16 
better than chance) to 1.0 (perfect discrimination). A C-statistic of 0.7-0.8 indicates modest 17 
discriminative ability, while a C-statistic greater than 0.8 indicates good discriminative 18 
ability. To describe score calibration, we similarly extracted data on the difference between 19 
the observed and predicted rates of pneumonia if available, as well as the ‘goodness of fit’ 20 
statistic and p-value of the corresponding test statistic. Calibration was considered better 21 
when the observed to predicted ratio was closer to 1.  22 
 23 
 24 
 25 
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Clinical usefulness  1 
We noted the complexity of application and use at the bedside, whether prediction scores 2 
incorporated categories of risk-stratification (usability), and whether scores had been used to 3 
evaluate clinical management or clinician behaviors (utility). We also evaluated the 4 
generalisability of each prediction model by determining whether it had been externally 5 
validated in an independent patient population, either in the original or subsequent 6 
publication. 7 
 8 
 9 
10 
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Findings 1 
Search results 2 
The electronic search yielded 2493 publications. After screening, exclusion of duplicates and 3 
applying eligibility criteria, 46 full texts and abstracts were reviewed (Figure 1). No 4 
additional articles were identified through hand-searching of major stroke journals or by the 5 
PISCES group. 12 fully published studies were finally considered eligible for inclusion.11, 18-6 
28
   7 
 8 
Clinical risk scores for predicting SAP  9 
14 separate cohorts were identified which had either derived or validated risk scores for 10 
predicting SAP (Online only Table III).  9 clinical risk-scores (Table 1) were identified 11 
from 8 derivation cohorts. The risk scores identified were: The Pneumonia Score,18  12 
Veteran’s Health Administration cohort score,11  A2DS2 (Age, Atrial fibrillation, Dysphagia, 13 
Severity [NIHSS], Sex) score,19  PANTHERIS (Preventive Antibacterial Therapy in Acute 14 
Ischaemic Stroke) score,20  AIS-APS (Acute Ischaemic Stroke-Associated Pneumonia 15 
Score),21  ICH-APS (Intracerebral Haemorrhage-Associated Pneumonia Score) A,22  ICH-16 
APS score B,22  Pneumonia (PNA) prediction score25 and ISAN (Prestroke Independence, 17 
Sex, Age, NIHSS) score.27  The number of components of each score varied between 3 and 18 
11. Age was a component of all scores, and the NIHSS score in all except the PANTHERIS 19 
score.20  Dysphagia (55%) and pre-morbid modified Rankin Scale (mRS, 36%) were other 20 
commonly used variables. 2 scores also included routine laboratory evaluation20,21  and 2 21 
scores incorporated neuroimaging features.22  The majority of the scores were derived only in 22 
ischaemic stroke patients (56%). The ISAN and the PNA prediction score included ICH 23 
patients in the derivation cohorts, 25, 27 while the ICH-APS scores22 were developed 24 
exclusively in ICH.  25 
10 
 
Study and participant characteristics  1 
Characteristics of the derivation and validation cohorts are summarised in Online only Table 2 
III. Median age was 71y (range 61y-76y) and median NIHSS was 5 (range 4-13). All studies 3 
adequately described selection of study sample. Except one study which was prospective, 26 4 
all were retrospective evaluations of existing prospective cohorts. Of the 14 separate 5 
derivation or validation cohorts, 8 (61%) were multicentre or national stroke registries and 6 6 
(39%) were single-centre hospital-based stroke registries. The majority of the 14 studies 7 
(80%) evaluated only acute ischaemic stroke.  Definition and ascertainment of risk factors for 8 
model derivation was varied and often limited by availability of data, particularly in existing 9 
national registries. For example, dysphagia assessment was not described among several 10 
studies, 21, 22, 25 and pre- stroke disability was described in different ways. 21,22,27  Some 11 
studies did not record pre-existing disability.18,25  Diagnostic approach to pneumonia varied 12 
between cohorts; clinician reported diagnosis of pneumonia (36%) and the CDC criteria for 13 
pneumonia (36%) were the most commonly used approaches. The other methods include 14 
adhoc objective criteria (14%) and Chinese Consensus criteria (14%).  15 
 16 
Quality assessment  17 
Overall, risk of bias and concerns regarding applicability were judged as generally low 18 
(Online only Table IV). In some validation cohorts, risk of bias was judged as high based on 19 
patient selection (exclusions based on incomplete baseline data27, or selected higher-risk 20 
cohort20), reference standard (non-standardised criteria for diagnosis of SAP11,19,27,28) and 21 
flow and timing (verification bias, related to differences in applying the same reference 22 
standard by the study group11,19,27,28 ). 23 
 24 
 25 
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Performance and validation of the risk-scores 1 
Performance and validation of the clinical risk scores is summarized in Table 2 and 3. C-2 
statistics ranged from 0.74-0.85 in the derivation cohorts, indicating a degree of 3 
discriminative performance that varied from modest to good. Only one score, the Pneumonia 4 
score, 18 did not report performance. Calibration was reported in 6 models using varying 5 
goodness of fit models or net reclassification index.  6 
 7 
6 of the risk-scores were validated internally through split samples (Table 2). All reported the 8 
C-statistic for the internal validation cohort, which ranged from 0.73 to 0.88, with 5 models 9 
reporting calibration metric. 5 of the 9 scores were validated externally (Table 3), with C-10 
statistic ranging from 0.68 to 0.83. The A2DS2 score19 has been evaluated most extensively, 11 
in the largest derivation sample (n=15,335), and in 8 separate external validation cohorts. The 12 
A2DS2 score performed consistently across these cohorts (C statistic 0.73 to 0.84), with good 13 
calibration.  14 
 15 
Clinical usefulness 16 
The risk-scores varied in their complexity and ease of use (Table 1), although most scores 17 
incorporated clinical variables readily available at baseline. 2 scores require admission 18 
laboratory variables20,21 and one of the scores developed exclusively for ICH requires 19 
quantitative measurement of hematoma volume.22  Several of the scores were stratified into 20 
integer-based risk categories11,19,21,22,27  (e.g. low, moderate, high risk), facilitating usability 21 
by clinicians. The role of implementing the models as prediction rules in terms of risk 22 
stratification, decision-making or improved patient outcomes was not evaluated for any of the 23 
scores.  24 
25 
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Discussion 1 
An ideal risk score for predicting SAP would incorporate variables readily available at stroke 2 
presentation, be quick to apply, provide meaningful risk categories with performance 3 
acceptable to the particular application (and to clinicians), and have impact on clinical 4 
decision-making and clinical outcomes. In this systematic review, we identified nine clinical 5 
risk scores for predicting SAP, and assessed their performance metrics, clinical usability and 6 
utility. We sought to identify whether any of the scores could be applied for use in clinical 7 
care or research.  8 
 9 
The scores varied considerably in their complexity, component variables, derivation cohort 10 
characteristics, approach to defining SAP, ease of application, consistency of external 11 
validation, and performance evaluation. Substantial heterogeneity between the studies was 12 
therefore anticipated and precluded meta-analyses. As previously acknowledged, 27 the 13 
prevalence of SAP varied between the cohorts, most likely related to underlying differences 14 
in patient characteristics and definitions used, 1 potentially contributing to outcome reporting 15 
bias. Several of the scores were derived from relatively small single centre cohorts18, 20, and 25 16 
limiting their generalisability. As all of the scores were derived using retrospective analyses 17 
of registry-based studies, model-building was limited by the baseline characteristics recorded 18 
in the different cohorts. Therefore, potentially important baseline characteristics (e.g. 19 
smoking, medication, chronic lung disease), medications (e.g. statin therapy or beta-20 
blockade), laboratory variables (e.g. leukocyte count or C-reactive protein [CRP]) or 21 
interventions (e.g. mechanical intervention, type of swallow screen), which may have 22 
influenced SAP risk, were not available in the majority of the derivation cohorts.  23 
  24 
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For the studies reporting performance metrics, the discriminative ability and calibration of the 1 
scores ranged from moderate to good.  However, several of the scores have not yet undergone 2 
external validation to our knowledge.20,22,25  Some of the scores performed similarly in the 3 
external validation and derivation cohorts,19,21,27  despite differences in patient characteristics, 4 
supporting generalisability. Importantly, the majority of the validation studies were unable to 5 
compare the performance of more than one score concurrently due to limitations imposed by 6 
data routinely collected in the registry-based cohorts. One study compared four scores 7 
concurrently, 21 and found no material difference in the performance metrics of the four 8 
scores (Pneumonia score, VHA score, AIS-APS, A2DS2) tested. Most scores were derived 9 
only in ischaemic stroke cohorts, although 2 scores with comparable performance were 10 
available for ICH. The ISAN and A2DS2 were evaluated in both ischaemic stroke and ICH, 11 
and performance metrics tended to be superior in ischaemic stroke rather than ICH, most 12 
likely due to ceiling effects.27   The only scores derived exclusively for ICH (ICH-APS A and 13 
B) are less practical to apply, requiring baseline imaging parameters, and have not been 14 
externally validated to date.22  Considering the high-rate of early neurological deterioration 15 
and conflicting risk of death after ICH, the ISAN, A2DS2 and ICH-APS scores each 16 
performed better, and comparably, in sensitivity analyses stratifying for survival beyond 48-17 
72 h after ICH.22,27 18 
 19 
The role of clinical risk-scores for predicting SAP in clinical care or research remains 20 
uncertain. None of the studies investigated utility in terms of clinician behaviours (for 21 
example, the time taken to administer the risk scores) or impact analysis on clinical 22 
outcomes. The current levels of sensitivity and specificity for given cut-offs on the scores19, 23 
21, 22, 24   may be unacceptable to clinicians, although this may depend on the particular 24 
application of the score. For example, for a cut-off of  ≥4 on the A2DS2 score, sensitivity is 25 
14 
 
91% but specificity is 57%.19  This means that only 9% of actual SAP cases are not identified 1 
as high-risk (false negative rate), yet 43% of the patients who do not get SAP are incorrectly 2 
identified as being at high-risk (false positive rate). For a safe, inexpensive and well-tolerated 3 
intervention to prevent SAP (e.g. enhanced monitoring or oral hygiene protocol) this extent 4 
of exposure to unnecessary interventions may be acceptable. However, for more expensive 5 
and complex preventive interventions with adverse effects, which are challenging to 6 
administer, then such low specificity may make clinical trials impractical and more difficult 7 
to justify.  8 
 9 
Further large, multi-centre prospective studies of consecutive patients, with adjudicated 10 
diagnosis of SAP using standardised and validated criteria are required to evaluate 11 
comparative performance and utility of the available scores. Refining the existing scores, 12 
including the addition of laboratory biomarkers such as CRP to improve performance, 26 13 
warrants further consideration. Finally, evaluating clinical utility of the scores is an essential 14 
step to determine effects on clinician behaviours, impact on clinical decision-making, clinical 15 
outcomes and feasibility of implementation.  16 
 17 
Conclusion  18 
We identified several clinical risk scores for predicting SAP which varied in their simplicity 19 
and consistency of validation. When recorded, performance metrics were comparable 20 
between scores, and no single score consistently performed better than others. However, 21 
interpretation was limited by heterogeneity and some risk of bias. The utility of risk scores 22 
for predicting SAP remains uncertain and requires further study in prospective cohorts with 23 
standardised criteria for definition of SAP. 24 
  25 
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Table 1: Components of clinical risk scores for predicting stroke-associated pneumonia 1 
 
 
ISAN A2DS2 AIS-
APS 
PANTHERIS VHA 
cohort 
Pneumonia 
score 
PNA 
prediction 
score 
ICH-
APS-A 
ICH-
APS-B 
Age          
NIHSS          
GCS          
Sex          
Dysphagia          
Mechanical ventilation          
Dysphasia          
OCSP subtype          
“Found-down”          
Increase in systolic BP 
> 200mmHg 
         
Comorbidities          
Pre-stroke dependence 
(mRS) 
         
Atrial fibrillation          
Congestive cardiac 
failure 
         
COPD          
Current smoking          
Excess alcohol 
consumption 
         
Previous pneumonia          
Diabetes          
Laboratory          
Blood glucose (mmol/l)          
WBC count /µl          
Radiology          
Infratentorial location          
Extension into 
ventricles 
         
Haematoma volume          
ISAN indicates Independence Prestroke, Sex, Age, National Institutes of Health Stroke Scale; A2DS2, Age, Atrial Fibrillation, Dysphagia  2 
Sex,  Severity; AIS-APS, Acute Ischaemic Stroke-Associated Pneumonia Score; PANTHERIS, Preventive Antibacterial Therapy in Acute 3 
Ischaemic Stroke; VHA, Veterans Health Administration; PNA, Pneumonia Prediction; ICH-APS, Intracerebral haemorrhage-Associated 4 
Pneumonia Score; NIHSS: National Institutes of Health Stroke Scale; GCS: Glasgow coma scale; OCSP: Oxfordshire community stroke 5 
project; mRS: modified Rankin scale; COPD: chronic obstructive pulmonary disease; WBC: White blood cell.   6 
   7 
 8 
  9 
19 
 
Table 2: Performance of the clinical risk scores for predicting SAP in the derivation and internal validation cohorts 
Score Derivation 
Cohort 
Size 
(n) 
Frequency of 
SAP (%) 
SAP 
diagnostic 
criteria 
Discrimination metric; C 
statistic (95% CI) 
Calibration metric 
ISAN score SSNAP 11551 6.7 Clinician 
reported 
0.79 (0.77 to 0.81) ‘well calibrated across all 22 levels in validation cohort; ceiling 
effect for score > 15 among ICH patients 
A2DS2 BSR 15335 7.2 Clinician 
reported 
0.84 (0.83-0.85) Cox and Snell R2 =0.106, Nagelkerke R2=0.259, McFadden R2 = 
0.213 
AIS-APS CNSR 8820 11.4 CDC 0.80 (0.78–0.81) NR 
PANTHERIS Berlin NICU 223 30 CDC 0.85 (0.80–0.91) Nagelkerke’s R2  0.46 
VHA score VHA 925 10.4 Clinician 
reported 
0.76 (NR) 2.1% misclassification 
Pneumonia score Seoul 286 10.5 Adhoc objective NR NR 
PNA score New-Orleans 568 11.4 Adhoc objective 0.79 (NR) NR 
ICH-APS(A) CNSR 2998 17 CDC 0.75 (0.72–0.77) Hosmer–Lemeshow goodness of fit test, P=0.20 
ICH-APS (B) CNSR 2998 17 CDC 0.74 (0.71–0.76) Hosmer–Lemeshow goodness of fit test, P=0.10 
Score Internal 
Validation 
Cohort 
Size 
(n) 
Frequency of 
SAP (%) 
SAP 
diagnostic 
criteria 
Discrimination metric; C 
statistic (95% CI) 
Calibration metric 
ISAN score SSNAP 11648 6.7 Clinician 
reported 
0.78 (0.76-0.80) NR 
AIS-APS CNSR 5882 11.3 CDC 0.79 (0.77–0.80) The Hosmer–Lemeshow test was not significant P=0.22 
PANTHERIS Berlin NICU 112 33.9 CDC 0.88 (0.81–0.95) Nagelkerke’s R2  = 0.48 
VHA score VHA 438 10.5 Clinician 
reported 
0.78 0.9% reclassification 
ICH-APS(A) CNSR 2000 16.7 CDC 0.76 (0.71–0.79) Hosmer–Lemeshow goodness of fit test, P=0.66 
ICH-APS (B) CNSR 2000 16.7 CDC 0.73 (0.70–0.76 Hosmer–Lemeshow goodness of fit test, P=0.17 
SAP indicates Stroke-Associated Pneumonia; ISAN, Independence Prestroke, Sex, Age, National Institutes of Health Stroke Scale; A2DS2, Age, Atrial, Fibrillation, Dysphagia, Sex, Severity; 
AIS-APS, Acute Ischemic Stroke-Associated Pneumonia Score; PANTHERIS, Preventive Antibacterial Therapy in Acute Ischaemic  Stroke; VHA, Veterans Health Administration; PNA, 
Pneumonia Prediction; ICH-APS, Intracerebral Haemorrhage-Associated Pneumonia Score; SSNAP, Sentinel Stroke National Audit Programme; BSR, Berlin Stroke Register; CNSR, Chinese 
National Stroke Registry; Berlin NICU, Berlin Neurological Intensive Care Unit; CDC, Centers for Disease Control and Prevention; NR, Not Reported; CI, Confidence Interval. 
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Table 3: Performance of the clinical risk scores for predicting SAP in the external validation cohorts 
Score External 
Validation cohort 
Size (n) Frequency of 
SAP (%) 
SAP diagnostic 
criteria 
Discrimination metric; C 
statistic (95% CI) 
Calibration metric 
ISAN  Athens 3204 12.8 Clinician reported 0.83 (0.81-0.85) The Hosmer–Lemeshow goodness of fit test  
(Cox and Snell R2 = 0.243) 
A2DS2 NWGSR 45085 7.8 Clinician reported 0.83 (0.83-0.84) Cox and Snell R2 = 0.112, Nagelkerke R2  =0.264, McFadden R2 =0.215 
 SSNAP 11648 6.7 Clinician reported 0.79 (0.77-0.81) NR 
 CNSR 8820 11.4.4 CDC 0.74 (0.73–0.75) NR 
 CNSR 5882 11.3 CDC 0.73 (0.72-0.74) NR 
 CICAS 3037 7.3 CDC 0.76 (0.74-0.77) NR 
 HNSR 1142 18.8 CDC 0.83 (0.8-0.87) Cox and Snell R2 = 0.243 
 WCH 1279 24 Chinese Expert 
Consensus 
NR NR 
 Shanghai 101 50.5 Chinese Expert 
Consensus 
0.82(0.74-0.9) NR 
AIS-APS CICAS 3 037 7.3 CDC 0.79 (0.76–0.82 The Hosmer–Lemeshow goodness of fit test;  
P=0.30 
 
VHA score CNSR 8820 11.4.4 CDC 0.75 (0.74–0.76) NR 
 CNSR 5882 11.3 CDC 0.73 (0.72–0.74) NR 
Pneumonia score CNSR 8820 11.4.4 CDC 0.71 (0.70–0.72) NR 
 CNSR 5882 11.3 CDC 0.69 (0.68–0.71) NR 
 CICAS 3037 7.3 CDC 0.68 (0.66–0.69) NR 
SAP indicates Stroke-Associated Pneumonia; ISAN, Independence Prestroke, Sex, Age, National Institutes of Health Stroke Scale; A2DS2, Age, Atrial Fibrillation, Dysphagia, Sex, Severity; 
AIS-APS, Acute Ischaemic Stroke-Associated Pneumonia Score; VHA, Veterans Health Administration; NWGSR, North West Germany Stroke Register; SSNAP, Sentinel Stroke National Audit 
Programme; CNSR, Chinese National Stroke Registry; CICAS, Chinese Intracranial Atherosclerosis Study; HNSR, Henan Province Stroke Registry; WCH; Wuhan Central Hospital; CDC, 
Centers for Disease Control and Prevention; NR, Not Reported; CI, Confidence Interval. 
 
 
